Evidence map›Paper›PMID 30868740›Full record

ArticleCancer medicine2019

Predictive factors of early recurrence after R0 resection of hilar cholangiocarcinoma: A single institution experience in China.

Hai-Jie Hu, Yan-Wen Jin, Anuj Shrestha, Wen-Jie Ma, Jun-Ke Wang, Fei Liu, Ya-Yun Zhu, Rong-Xing Zhou, Parbatraj Regmi, Nan-Sheng Cheng and 1 more

Abstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Application of AI on cholangiocarcinoma.Frontiers in oncology · 2024
    Review
  5. Article
  6. New Imaging Techniques.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Rectal stenosis due to solitary pelvic recurrence of hilar cholangiocarcinoma.JGH open : an open access journal of gastroenterology and hepatology · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hai-Jie HuDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Yan-Wen JinDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Anuj ShresthaDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Wen-Jie MaDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Jun-Ke WangDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Fei LiuDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Ya-Yun ZhuDepartment of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Rong-Xing ZhouDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Parbatraj RegmiDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Nan-Sheng ChengDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Fu-Yu LiDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.ORCID 0000-0003-2755-2887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prediction of early postoperative recurrence is of great significance for follow-up treatment. However, there are few studies available that focus on high-risk factors of early postoperative recurrence or even the definition the exact time of early recurrence for hilar cholangiocarcinoma. Thus, we aimed to examine the optimal cut-off value for defining the early in patients with R0 resection of hilar cholangiocarcinoma and to investigate prognostic factors associated with early recurrence. Two hundred and fifty-eight patients with R0 resection of hilar cholangiocarcinoma between 2000 and 2015 were included. The minimum P value approach was used to define the optimal cut-off of early recurrence. The prognostic factors associated with early recurrence were investigated. The optimal cut-off value for dividing patients into early and non-early recurrence groups after R0 resection of hilar cholangiocarcinoma was 12 months. Sixty-two patients were recorded as early recurrence, and the remaining 196 patients were labeled as non-early recurrence. Multivariate logistic regression analysis indicated lymph node metastasis (OR = 2.756, 95% CI 1.409-5.393; P = 0.003), poor differentiation (OR = 1.653; 95% CI 1.040-2.632; P = 0.034), increased postoperative CA 19-9 levels (OR = 1.965, 95% CI 1.282-3.013; P = 0.002), neutrophil-to-lymphocyte ratio > 3.41 (OR = 5.125, 95% CI 2.419-10.857; P < 0.001) and age > 60 years (OR = 2.018, 95% CI 1.032-3.947; P = 0.040) were independent determinants of early and non-early recurrence. Poor differentiation (HR = 2.609, 95% CI 1.600-4.252; P < 0.001), Bismuth classification type III/IV (HR = 2.510, 95% CI 1.298-4.852; P = 0.006) and perineural invasion (HR=2.380, 95% CI 1.271-4.457; P = 0.007) were independent factors of overall survival in the subgroup of patients who developed early recurrence. The optimal cut-off value for dividing early recurrence after R0 resection of hilar cholangiocarcinoma was 12 months. Tumor differentiation, Bismuth classification, and perineural invasion were independent factors of overall survival in the subgroup of patients with early recurrence. Patients with risk factors should be monitored closely after curative surgery.

Indexed as

AdultAgedAged, 80 and overBile Duct NeoplasmsFemaleFollow-Up StudiesHumansKaplan-Meier EstimateKlatskin TumorMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPreoperative Careearly recurrencehilar cholangiocrcinomaprognosissurvival

Identifiers

PMID30868740
PMCPMC6488134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.